---
figid: PMC3804031__nihms509444f3
figtitle: Targeting the RAS oncogene
organisms:
- NA
pmcid: PMC3804031
filename: nihms509444f3.jpg
figlink: /pmc/articles/PMC3804031/figure/F3/
number: F3
caption: 'While these mutant BRAF inhibitors produce improved overall survival in
  the patients with BRAF mutations compared to standard treatment options, a major
  challenge remains: essentially all patients treated with these drugs relapse due
  to the development of drug resistance, with the median TTP of 7 months for vemurafenib
  and 5 months for dabrafenib (, ). Several models for resistance have been proposed:
  1) reactivation of the MEK/ERK pathway bypassing BRAF (e.g., secondary mutation
  in NRAS, hyperactivation/overexpression of C-Raf, or activation of another MAPKK
  COT); or, 2) adaptive dependency upon alternative pathways (hyperactivation/overexpression
  of RTKs, such as PDGFRβ or IGF1R, or the AKT pathway) () (–).'
papertitle: Targeting the RAS oncogene.
reftext: Asami Takashima, et al. Expert Opin Ther Targets. ;17(5):507-531.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9532521
figid_alias: PMC3804031__F3
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC3804031__F3
ndex: 19588d9f-deb2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3804031__nihms509444f3.html
  '@type': Dataset
  description: 'While these mutant BRAF inhibitors produce improved overall survival
    in the patients with BRAF mutations compared to standard treatment options, a
    major challenge remains: essentially all patients treated with these drugs relapse
    due to the development of drug resistance, with the median TTP of 7 months for
    vemurafenib and 5 months for dabrafenib (, ). Several models for resistance have
    been proposed: 1) reactivation of the MEK/ERK pathway bypassing BRAF (e.g., secondary
    mutation in NRAS, hyperactivation/overexpression of C-Raf, or activation of another
    MAPKK COT); or, 2) adaptive dependency upon alternative pathways (hyperactivation/overexpression
    of RTKs, such as PDGFRβ or IGF1R, or the AKT pathway) () (–).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - bo
  - Raf
  - Akt
  - 'On'
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - EGFR
  - ERBB2
  - PDGFRB
  - PDGFRA
  - IGF1R
  - KRAS
  - HRAS
  - NRAS
  - PEE1
  - MTG1
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
